HLA and other host factors in transfusion-acquired HIV-1 infection

Geczy, Andrew F.; Kuipers, Harmjan; Coolen, Marcel W.; Ashton, Lesley J.; Kennedy, C.; Ng, G.; Dodd, R.; Wallace, R.; Lе, Trаng; Raynes‐Greenow, Camille; Dyer, Wayne B.; Learmont, Jennifer; Sullivan, John S.

doi:10.1016/s0198-8859(99)00142-1

Cited by 19 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inconsistencies in favorable and unfavorable associations with disease progression were detected for most of the HLA-A supertype alleles. The patterns remained unchanged after excluding two alleles that appeared to be associated with protection in our analysis (P Ͻ 0.01): A*32, an allele that has been associated with protection elsewhere (13,21,44), was excluded from A1s; and A*74, associated with favorable HIV-1 outcomes here only, was excluded from A3s.…”

Section: Resultsmentioning

confidence: 93%

Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans

Lazaryan

Song

Lobashevsky

et al. 2010

J Virol

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 93%

Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans

Lazaryan

Song

Lobashevsky

et al. 2010

J Virol

View full text Add to dashboard Cite

“…after the second dose as well (OR ϭ 5.3, P Ͻ 0.05), and it remained strong throughout the postvaccination period, even when vaccinees with B‫72ء‬ and B‫75ء‬ were excluded (see below). A‫23ء‬ has been associated with relatively slow disease progression in two related population studies (26,30), and a trend toward protection was seen in a small group of transfusion recipients with long-standing infection (15). For A‫,1020ء‬ the most common allele and one prominently featured in experimental protocols, during the interval through the third or fourth dose, positive CTL responses occurred in somewhat ϩ CTL responses to major HIV protein components by 2 weeks after the third or fourth dose (26 weeks after enrollment) are shown.…”

Section: Resultsmentioning

confidence: 99%

Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines

Kaslow

Rivers

Tang

et al. 2001

J Virol

View full text Add to dashboard Cite

Carriers of certain human leukocyte antigen class I alleles show favorable prognosis of human immunodeficiency virus type 1 (HIV-1) infection, presumably due to effective CD8؉ cytotoxic T-lymphocyte responses, but close relationships between class I variants mediating such responses to natural and to vaccine HIV-1 antigen have not been established. During 6 to 30 months of administration and follow-up in trials of ALVAC-HIV recombinant canarypox vaccines, cells from 42% of 291 HIV-1-negative vaccinated subjects typed at class I loci responded to an HIV-1 protein in a lytic bulk CD8؉ cytotoxic T-lymphocyte assay. By 2 weeks after the second dose, higher proportions of vaccinees carrying one of two alleles consistently associated with slower progression of natural HIV-1 infection reacted at least once: B‫72ء‬ carriers reacted to Gag (64%; odds ratio [OR] ‫؍‬ 10.3, P ‫؍‬ 0.001) and Env (36%; OR ‫؍‬ 4.6, P ‫؍‬ 0.04), and B‫75ء‬ carriers reacted to Env (44%; OR ‫؍‬ 6.6, P < 0.05). By 2 weeks after the third or fourth dose, B‫72ء‬ carriers had responded (two or more reactions) to Gag (33%; OR ‫؍‬ 4.4, P < 0.05) and B‫75ء‬ carriers had responded to both Gag (39%; OR ‫؍‬ 5.3, P ‫؍‬ 0.013) and Env (39%; OR ‫؍‬ 9.5, P ‫؍‬ 0.002). Homozygosity at class I loci, although conferring an unfavorable prognosis following natural infection, showed no such disadvantage for vaccine response. Individual class I alleles have not previously demonstrated such clear and consistent relationship with both the clinical course of an infection and cellular immunity to a vaccine against the infectious agent. This proof of principle that class I an alleles modulate both processes has implications for development of HIV-1 and presumably other vaccines.

show abstract

“…Two patients (patients 9 and 10) expressed both HLA-A2 and HLA-B8 (Fig. 8b), which allowed staining for the HLA-A2/HPV16 E7 [11][12][13][14][15][16][17][18][19][20] and the B8/E7 7-13 tetramer complex. CD8…”

Section: Tlheymldl-specific T Cells Are Present In Tils and Tumor-dramentioning

confidence: 99%

“…ϩ PBLs tested positive for tetramer binding of HPV16 E7 either presented by HLA-A2 (amino acids [11][12][13][14][15][16][17][18][19][20] or HLA-B8 (amino acids 7-15) and antigenspecific T cells resided in the CD45RA ϩ CCR7 ϩ or in the CD45RA ϩ CCR7 Ϫ T-cell subset (Fig. 8b).…”

Section: Tlheymldl-specific T Cells Are Present In Tils and Tumor-dramentioning

confidence: 99%

See 1 more Smart Citation

Naturally processed and HLA‐B8‐presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer

Oerke¹,

Höhn²,

Zehbe³

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Several major histocompatibility complex (MHC) alleles have been reported to present peptides derived from the HPV16 E7 oncoprotein to T cells. We describe an overrepresentation of the HLA-B8 allele (28.44%) in cervical cancer patients as compared to the MHC class I allele frequency in a local healthy control population (18.80%) and the identification of an HLA-B8-binding peptide TLHEYMLDL (HPV16 E7 7-15 ), which is able to drive HPV16 E7-specific and MHC class I-restricted T-cell responses in peripheral blood lymphocytes from healthy individuals. TLHEYMLDLspecific T cells recognize the naturally processed and presented peptide on HPV16؉ cervical cancer cells transfected with the HLA-B8 gene defined by IFN-␥ production. This peptide epitope is also recognized by freshly harvested tumor-infiltrating T cells or T cells from tumor-draining lymph nodes from patients with cervical cancer determined by flow cytometry as well as by tetramer in situ staining. HLA-B8-restricted HPV E7 7-15 -specific T cells reside predominantly in the CD8 ؉ CD45RA ؉ CCR7 ؉ precursor or in the differentiated CD8 ؉ CD45RA ؉ CCR7 ؊ T-cell population.

show abstract

HLA and other host factors in transfusion-acquired HIV-1 infection

Cited by 19 publications

References 26 publications

Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans

Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans

Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines

Naturally processed and HLA‐B8‐presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer

Contact Info

Product

Resources

About